Testolactone treatment of precocious puberty in McCune-Albright syndrome

C. M. Foster, O. H. Pescovitz, F. Comite, P. Feuillan, T. Shawker, D. L. Loriaux, G. B. Cutler

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.

Original languageEnglish (US)
Pages (from-to)254-257
Number of pages4
JournalActa Endocrinologica
Issue number2
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Testolactone treatment of precocious puberty in McCune-Albright syndrome'. Together they form a unique fingerprint.

Cite this